Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Refractory Depression Clear all
Completed Phase 2Phase 3 Interventional Results available

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

NCT03113968
View directory record Official record
Conditions
Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
Interventions
electroconvulsive therapy (ECT), Ketamine
Procedure · Drug
Lead sponsor
Bo Hu
Other
Eligibility
21 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991
View directory record Official record
Conditions
Depression
Interventions
Brexpiprazole, Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Treatment Resistant Depression and Insomnia in Older Veterans

NCT02971150
View directory record Official record
Conditions
Treatment Resistant Depression, Insomnia
Interventions
Brief Behavioral Treatment for Insomnia
Behavioral
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jun 10, 2026, 4:50 AM EDT
Terminated Phase 1 Interventional

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

NCT02675556
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Allo-hMSCs, Placebo
Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Not yet recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Jun 10, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Computational Psychiatric Approach to Depression

NCT04189939
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
clinical assessments
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

NCT02046330
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Deep Brain Stimulation Model 3387 Model 3389
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine for Late-Life Treatment Resistant Depression

NCT01071538
View directory record Official record
Conditions
Depression
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

NCT03191058
View directory record Official record
Conditions
Depression, Unipolar Depression, Treatment Resistant Depression
Interventions
Magnetic Seizure Therapy, Electroconvulsive Therapy
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression

NCT00034229
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Felbamate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Transcranial Magnetic Stimulation for Depression in Autism Spectrum Conditions

NCT05271357
View directory record Official record
Conditions
Autism Spectrum Disorder, Major Depressive Disorder
Interventions
Bilateral TMS, Unilateral TMS
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 26 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

BPL-003 Efficacy and Safety in Treatment Resistant Depression

NCT05870540
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
BPL-003
Drug
Lead sponsor
Beckley Psytech Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

NCT02452892
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
Interventions
LFMS
Device
Lead sponsor
Tal Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S

NCT01984710
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic Activa PC+S System
Device
Lead sponsor
Emory University
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression

NCT03953417
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Accelerated intermittent theta-burst treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 4:50 AM EDT